Study on Early Brain Injury Mechanism and Comprehensive Intervention of VCI
NCT04999813 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2021-08-11
Summary
Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of senile dementia. Although the animal research of dementia has made remarkable progress, clinical trials of drugs for AD pathology have failed in recent years. The study of dementia based on cell and animal model generally aims at a single mechanism and target, and its results are quite different from the real clinical environment. More and more studies suggest that investigators should shift the focus of research to the early stage of cognitive impairment before dementia. Prevention is more important than cure, and intervention against multi-factors and multi-targets has become an important consensus. A large number of studies have shown that the mechanism of vascular brain injury plays an important role in the pathogenesis of AD and VaD, and many vascular risk factors are interventionable to some extent. Therefore, based on the clinical cohort, in-depth study of vascular cognitive impairment (Vascular cognitive impairment, VCI) has important clinical significance for the effective prevention and treatment of AD and VaD.
The leading team of the project has focused on VCI research for a long time. After nearly 20 years of experimental research and preliminary clinical observation, it is proposed that chronic cerebral ischemia can not only be a clinical disease entity, but also an important pathological basis for the early onset of VCI. This view has recently been supported by a number of authoritative international research evidence. Big data's study of 1171 patients with AD reported by Nature Commun in 2016 shows that the early pathological changes of AD may not be a cascade of amyloid protein (Aβ), but a decrease in cerebral blood flow. Therefore, this project intends to establish an early clinical research cohort of VCI to focus on three key issues in VCI research and clinical practice: (1) the theory that cerebral hypoperfusion may be an important pathological basis for the occurrence and development of VCI needs direct evidence support from clinical studies, and its mechanism needs further elucidation. (2) Based on the fusion of multimodal MRI of VCI vascular brain injury pathology and PET imaging markers of Aβ molecular pathology, a multivariate VCI cognitive evaluation model is constructed, and its sensitivity and specificity may be better than the existing VCI diagnostic standards. (3) the protective effect of early comprehensive intervention of vascular risk factors on cognitive decline in VCI may be more effective than that of single risk factor.
The first part of this project is to establish a study cohort of non-demented vascular cognitive impairment(VCIND). Neurocognitive function assessment combined with multimodal MRI including ASL, DCE, DTI and BOLD techniques were used to observe the role of cerebral hypoperfusion in the early stage and progression of VCI. At the same time, the relationship between the changes of blood-brain barrier and neural network and cognitive decline was dynamically observed to verify and explore the effect and mechanism of cognitive impairment caused by cerebral hypoperfusion. The second part studies the pathology of vascular brain injury based on MRI and the molecular pathology of A β based on PET and the relationship between Aβ molecular pathology and cognitive impairment, including the main factors affecting cognitive function, and uses artificial intelligence (AI) algorithm to develop a multiple quantitative evaluation system of VCI cognitive function, which is mainly based on the fusion of MRI and PET image markers. In the third part, a multicenter randomized controlled clinical cohort study was conducted to observe the cognitive protective effect of comprehensive intensive intervention of vascular risk factors on early VCI, so as to provide direct clinical evidence and intervention model for the prevention and treatment of VCI. The topics of the above three aspects covered by this project are closely related, which is not only a key scientific problem, but also an important clinical problem to be solved in the diagnosis and treatment of VCI.
The study of this project is expected to further clarify the role and mechanism of cerebral hypoperfusion in VCI, provide a new theoretical basis for the prevention and treatment of dementia, and develop a quantitative evaluation system of VCI cognitive function mainly based on imaging technology and AI algorithm, so as to provide a more accurate and convenient diagnostic tool for early clinical identification and scientific research of VCI. Draw up the early comprehensive intervention paradigm of VCI based on vascular risk factors and popularize it in clinic, gradually form an expert consensus, enrich and update the guidelines for diagnosis and treatment of dementia, and effectively improve the level of prevention and treatment of dementia related to VCI.
Conditions
- Vascular Cognitive Impairment
Interventions
- COMBINATION_PRODUCT
-
Comprehensive intensive intervention
* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake. * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time. * Weight loss guidance.
Sponsors & Collaborators
-
Zhongnan Hospital
lead OTHER
Principal Investigators
-
Zhipeng Xu, Ph. D. · Zhongnan Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-07-01
- Primary Completion
- 2023-11-30
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
NCT04309253 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease
NCT04137926 ·Status: UNKNOWN ·Phase: NA
-
Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials.
NCT04860414 ·Status: COMPLETED ·Phase: NA
-
Comparative Study Between Alzheimer's and Multi-infarct Dementia
NCT05781139 ·Status: RECRUITING
-
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT06619613 ·Status: RECRUITING ·Phase: PHASE1
-
Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management
NCT05641480 ·Status: RECRUITING ·Phase: NA
-
Discovering Factors in the Clinical Trial Journey of Dementia Patients
NCT05850000 ·Status: NOT_YET_RECRUITING
-
Brain Imaging and Mental Disorders of Aging Intervention
NCT00267163 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia
NCT03230071 ·Status: COMPLETED ·Phase: PHASE2
-
Brain Imaging in Alzheimer's Disease
NCT00039702 ·Status: COMPLETED
-
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
NCT06868030 ·Status: NOT_YET_RECRUITING
-
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT04305210 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill
NCT04958512 ·Status: COMPLETED ·Phase: NA
-
Deep Brain Stimulation for Alzheimer's Disease
NCT03959124 ·Status: UNKNOWN ·Phase: NA
-
Symptomatic Treatment of Vascular Cognitive Impairment
NCT02098824 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
NCT06530732 ·Status: RECRUITING ·Phase: PHASE3
-
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
NCT00104442 ·Status: COMPLETED ·Phase: PHASE4
-
Bisnorcymserine in Healthy Adult Volunteers
NCT01747213 ·Status: COMPLETED ·Phase: PHASE1
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT02565511 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
NCT02931136 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Feasibility Study of Transcranial Ultrasound Stimulation on Alzheimer's Disease Patients
NCT03896698 ·Status: UNKNOWN ·Phase: NA
-
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
NCT03090516 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02788513 ·Status: COMPLETED ·Phase: PHASE2